Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Vaccination coverage in children up to 2 years old born in 2017 and 2018 in the municipalities of SĂŁo Paulo and Campinas, Brazil: comparison of the results of a national survey and the National Immunization Program Information System.
Epidemiol Serv Saude
January 2025
Universidade de BrasĂlia, BrasĂlia, DF, Brazil.
Objective: To estimate and compare vaccination coverage among children born in 2017-2018 in SĂŁo Paulo and Campinas, according to the Vaccination Coverage Survey (ICV 2020) and the National Immunization Program Information System (SI-PNI).
Methods: ICV 2020 analyzed vaccination card records. Coverage was calculated and compared to doses recorded on the SI-PNI, divided by the target population.
Clinical outcome of BCG treatment for patients with urothelial carcinoma of the prostatic urethra: Implications for early cystectomy.
World J Urol
January 2025
Department of Urology, Saint Marianna University School of Medicine, Kawasaki, Japan.
Purposes: This study aimed to clarify the clinical outcomes of Bacillus Calmette-Guérin (BCG) treatment in patients with urothelial carcinoma (UC) of the prostatic urethra.
Methods: Between August 2003 and January 2023, 428 patients with non-muscle-invasive UC received BCG treatment (Tokyo strain, 80 mg, ≥ 5 times) in our hospital; 39 had UC of the prostatic urethra. We evaluated the cumulative incidence of intravesical recurrence, progression (muscle-invasive bladder cancer [MIBC] or metastasis), and subsequent radical cystectomy after BCG treatment in patients with UC of the prostatic urethra.
Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate.
Sci Rep
January 2025
The Jenner Institute, University of Oxford, Oxford, UK.
BCG remains the only licensed vaccine for tuberculosis (TB), but its efficacy wanes over time. Subunit vaccines, aim to improve BCG immunity and protection, by inducing responses to a few mycobacterial antigens delivered with a specific platform. Since the platform shapes the immune response induced, selecting the right platform has been challenging due to the lack of immune correlates of protection.
View Article and Find Full Text PDFLong-term evaluation in BALBc mice of a triple mutant of Mycobacterium bovis and the Bacillus Calmette-Guérin as potential vaccines against bovine tuberculosis.
Vet Microbiol
January 2025
Instituto de AgrobiotecnologĂa y BiologĂa Molecular, (IABIMO) INTA-CONICET, Argentina; Instituto de BiotecnologĂa, CICVyA, Instituto Nacional de TecnologĂa Agropecuaria, N. Repetto and De los Reseros, Hurlingham, Buenos Aires 1686, Argentina. Electronic address:
There is currently no commercial vaccine available against bovine tuberculosis (bTB). Mycobacterium bovis is the primary causative agent of bTB and is closely related to Mycobacterium tuberculosis, the pathogen responsible for human TB. Despite their limitations, mouse models are invaluable in early vaccine development due to their genetic diversity, cost-effectiveness, and the availability of research tools.
View Article and Find Full Text PDFA BCG kill switch strain protects against Mycobacterium tuberculosis in mice and non-human primates with improved safety and immunogenicity.
Nat Microbiol
January 2025
Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Improved vaccination strategies for tuberculosis are needed. Intravenous (i.v.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!